BEAM

Beam Therapeutics' stock has experienced momentum with positive one-month and one-year share price returns, although longer-term returns remain negative. Positive clinical data for BEAM-302 and the sickle cell program, a narrower net loss in first-quarter 2026 results, a $500 million financing agreement, and M&A speculation have positively influenced the stock. Geopolitical risks and insider stake reduction have exerted downward pressure.